GCF Levels of Chemokines in Periodontitis

CCL19/MIP3beta and CCL20/MIP3alpha Levels in the Gingival Crevicular Fluid of the Patients With Stage III Grade B and C Periodontitis

This study aimed to determine CCL19/MIP3beta(β) and CCL20/MIP3alpha(α) in the gingival crevicular fluid (GCF) of the patients with different periodontitis phenotypes.

A total of 72 individuals, 24 with Stage III Grade B periodontitis (Group 1), 24 with Stage III Grade C periodontitis (Group 2), and 24 periodontally healthy (control group) (Group 3), were included in the study. GCF and clinical periodontal parameters were obtained at baseline. MIP3β and MIP3α levels in GCF were determined by ELISA.

Study Overview

• Status: Completed
• Conditions: Periodontal Diseases
• Intervention / Treatment: Diagnostic test: Routine periodontal examination

• Study Type: Observational
• Enrollment (Actual): 72

Contacts and Locations

Study Locations

• Turkey
  • Ordu, Turkey, 52100
    • Ordu University, Faculty of Dentistry

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

• Group 1: Stage III Grade B periodontitis group
• Group 2: Stage III Grade C periodontitis group
• Group 3: Periodontally healthy control group

Description

Inclusion Criteria:

• Have at least 20 natural teeth, excluding third molars.
• Periodontitis patients had at least two non-adjacent sites per quadrant with probing depth (PD) ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm with gingival inflammation, and alveolar bone loss affecting >30% of the teeth, as detected on clinical and radiographical examinations.
• Periodontally healthy control group had no sign of gingival inflammation, no PD > 3mm and no evidence of attachment or bone loss

Exclusion Criteria:

• History of systemic disease.
• Regular use of any drugs which can effect the immune system or inflammatory response in the 6 months preceding the start of the study.
• Periodontal treatment during last 6 months that could affect periodontal status.
• Smoking.
• History of radiotherapy or chemotherapy.
• Current pregnancy, lactation or menopause.

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Stage III Grade B periodontitis group (Group 1); Stage III Grade B periodontitis patients and systemically healthy	Diagnostic test: Routine periodontal examination; In all of the patients, the following indexes were used routinely for the periodontal examination: Sillness-Löe's plaque index (PI) (Silness & Löe, 1964), Löe-Sillness's gingival index (GI)(Löe & Silness, 1963), probing depth (PD) to measure the extent and severity of periodontal disease, clinical attachment level (CAL), and bleeding on probing (BOP)(Ainamo & Bay, 1975) to determine activity. In addition, routine radiographic evaluations were performed to determine bone levels.GCF samples were collected using standardized filter papers.
Stage III Grade C periodontitis group (Group 2); Stage III Grade C periodontitis patients and systemically healthy	Diagnostic test: Routine periodontal examination; In all of the patients, the following indexes were used routinely for the periodontal examination: Sillness-Löe's plaque index (PI) (Silness & Löe, 1964), Löe-Sillness's gingival index (GI)(Löe & Silness, 1963), probing depth (PD) to measure the extent and severity of periodontal disease, clinical attachment level (CAL), and bleeding on probing (BOP)(Ainamo & Bay, 1975) to determine activity. In addition, routine radiographic evaluations were performed to determine bone levels.GCF samples were collected using standardized filter papers.
Control group (Group 3); Periodontally healthy (control group) and systemically healthy patients	Diagnostic test: Routine periodontal examination; In all of the patients, the following indexes were used routinely for the periodontal examination: Sillness-Löe's plaque index (PI) (Silness & Löe, 1964), Löe-Sillness's gingival index (GI)(Löe & Silness, 1963), probing depth (PD) to measure the extent and severity of periodontal disease, clinical attachment level (CAL), and bleeding on probing (BOP)(Ainamo & Bay, 1975) to determine activity. In addition, routine radiographic evaluations were performed to determine bone levels.GCF samples were collected using standardized filter papers.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CCL19/MIP3beta(β) levels	CCL19/MIP3beta(β) levels in the gingival crevicular fluid (GCF) of the all groups	Baseline
CCL20/MIP3alpha(α) levels	CCL20/MIP3alpha(α) levels in the gingival crevicular fluid (GCF)	Baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CCL19/MIP3beta(β) levels and clinical parameters	Correlation between CCL19/MIP3beta(β) levels in the gingival crevicular fluid (GCF) of the all groups and all clinical parameters	Baseline
CCL20/MIP3alpha(α) levels and clinical parameters	Correlation between CCL20/MIP3alpha(α) levels in the gingival crevicular fluid (GCF) of the all groups and all clinical parameters	Baseline

Collaborators and Investigators

• Sponsor: T.C. ORDU ÜNİVERSİTESİ

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2023
• Primary Completion (Actual): December 1, 2023
• Study Completion (Actual): December 1, 2023

Study Registration Dates

• First Submitted: February 22, 2024
• First Submitted That Met QC Criteria: February 29, 2024
• First Posted (Actual): March 4, 2024

Study Record Updates

• Last Update Posted (Actual): March 8, 2024
• Last Update Submitted That Met QC Criteria: March 6, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Stomatognathic Diseases; Mouth Diseases; Periodontitis; Periodontal Diseases
• Other Study ID Numbers: 741100

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No